Chemomab Therapeutics Ltd (CMMB) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing...

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companieswith “Key, Near-Term...

Form POS AM - Post-Effective amendments for registration statement

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

—Clinical Data from Phase 2 SPRING Trial Shows that CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

──FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated...

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or...

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

TEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]